TNFSF11 and plasma cell myeloma: Importantly, Embelin can suppress receptor activator of nuclear factor kappa-B ligand (RANKL) induced osteoclastogenesis in vitro in RAW 264.7 cells and in myeloma and breast cancer cells [28]; however no studies have assessed the effect of Embelin on bone erosion in vivo.